JEFFREY WILLEY: Open Payments
NPI 1407610983 · SEAFORD, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$676 in 32 payments from 14 companies in 2025. Trend: 2023 $0 · 2024 $358 · 2025 $676
Food & beverage: $676
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 4 | $91 |
| Alkermes, Inc. | 4 | $86 |
| ABBVIE INC. | 4 | $85 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $82 |
| Lundbeck LLC | 4 | $78 |
| IDORSIA PHARMACEUTICALS US INC | 2 | $45 |
| Neurocrine BioSciences, Inc. | 2 | $41 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $35 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
Products named: REXULTI, UZEDY, ARISTADA, VRAYLAR, CAPLYTA, Quviviq, INGREZZA, Auvelity.
Industry payments across DE — which companies pay providers there.
